Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, Panteleimon G. Takis et al.|Nature Medicine|2023Cited by 446
Single-cell spatial immune landscapes of primary and metastatic brain tumoursElham Karimi, Logan A. Walsh, Miranda W. Yu et al.|Nature|2023Cited by 397
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, Mathieu Lajoie et al.|Clinical Cancer Research|2018Cited by 76
<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitorsMarion Tonneau, Bertrand Routy, Alexis Nolin-Lapalme et al.|OncoImmunology|2022Cited by 29
Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinationsApril A. N. Rose, Peter M. Siegel, Matthew Dankner et al.|Molecular Cancer Therapeutics|2018Cited by 1